The Journal.
The Journal.

Sep 2, 2026 · 18 min

GLP-1 drugs push Big Food beyond indulgence

How Big Food Is Navigating the GLP-1 Era

As GLP-1 users eat less and seek more protein and fiber, food companies must adapt products without abandoning the broader market for traditional snacks.

3 key takeaways
  1. 1GLP-1 drugs are reducing cravings and reshaping demand for salty snacks, baked goods, and other indulgent foods.
  2. 2Companies are testing higher-protein, higher-fiber recipes and packaging claims while confronting the technical limits of satisfying reformulated products.
  3. 3Data and AI tools are helping food makers model GLP-1 consumers as they build a playbook for a potentially lasting shift.

Don't miss

The episode reveals that General Mills created an AI persona named Lisa to represent a GLP-1 user during product development.

The brief

At a Conagra test kitchen, chefs evaluate packaged breakfast foods for satisfaction, offering a close-up view of how GLP-1 drugs are changing product development.

GLP-1 users may feel less hunger, fewer cravings, and altered taste, putting pressure on a food model built around sugar, salt, and indulgence.

The shift reaches beyond individual users: households are seeking more protein, fiber, and fresher foods while companies test claims and reformulations that still taste satisfying.

General Mills is using AI personas, including a fictional GLP-1 user named Lisa, alongside purchasing and social-media data to speed product decisions.

Executives see GLP-1s as more durable than past diet trends, but the emerging playbook keeps high-fat, high-salt, and high-sugar products for consumers who still want them.

Weekly email

State of the Pod, every Monday

The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.

Listen to the full episode and explore every guest, topic, and moment on PodLume.